JP2023537632A5 - - Google Patents
Info
- Publication number
- JP2023537632A5 JP2023537632A5 JP2023511616A JP2023511616A JP2023537632A5 JP 2023537632 A5 JP2023537632 A5 JP 2023537632A5 JP 2023511616 A JP2023511616 A JP 2023511616A JP 2023511616 A JP2023511616 A JP 2023511616A JP 2023537632 A5 JP2023537632 A5 JP 2023537632A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- groups
- halo
- optionally substituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026036645A JP2026116909A (ja) | 2020-08-14 | 2026-03-06 | 疼痛の処置のためのＮａＶ１．７の非水和ケトン阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063066012P | 2020-08-14 | 2020-08-14 | |
| US63/066,012 | 2020-08-14 | ||
| PCT/US2021/046054 WO2022036297A1 (en) | 2020-08-14 | 2021-08-14 | Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026036645A Division JP2026116909A (ja) | 2020-08-14 | 2026-03-06 | 疼痛の処置のためのＮａＶ１．７の非水和ケトン阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537632A JP2023537632A (ja) | 2023-09-04 |
| JP2023537632A5 true JP2023537632A5 (enExample) | 2024-09-02 |
Family
ID=77693595
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023511616A Pending JP2023537632A (ja) | 2020-08-14 | 2021-08-14 | 疼痛の処置のためのＮａＶ１．７の非水和ケトン阻害剤 |
| JP2026036645A Pending JP2026116909A (ja) | 2020-08-14 | 2026-03-06 | 疼痛の処置のためのＮａＶ１．７の非水和ケトン阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026036645A Pending JP2026116909A (ja) | 2020-08-14 | 2026-03-06 | 疼痛の処置のためのＮａＶ１．７の非水和ケトン阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230339958A1 (enExample) |
| EP (2) | EP4196482B1 (enExample) |
| JP (2) | JP2023537632A (enExample) |
| KR (1) | KR20230051252A (enExample) |
| CN (1) | CN116368139A (enExample) |
| AU (1) | AU2021326546A1 (enExample) |
| BR (1) | BR112023002659A2 (enExample) |
| CA (1) | CA3188924A1 (enExample) |
| ES (1) | ES3061196T3 (enExample) |
| IL (1) | IL300626A (enExample) |
| MX (1) | MX2023001741A (enExample) |
| WO (1) | WO2022036297A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3058214A1 (en) | 2017-03-29 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | 11,13-modified saxitoxins for the treatment of pain |
| EP3860714B1 (en) | 2018-10-03 | 2023-09-06 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
| CA3221939A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| CN117794918A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃类似物作为钠通道调节剂 |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| US20240368135A1 (en) | 2021-06-04 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| SMT202600064T1 (it) | 2021-06-04 | 2026-03-09 | Vertex Pharma | Forme farmaceutiche solide e regimi di dosaggio comprendenti (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metossi-fenil)-4,5-dimetil-5-(trifluorometil) tetraidrofuran-2-carbonil]ammino]piridin-2-carbossammide |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| AU2023255558A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| IL316422A (en) | 2022-04-22 | 2024-12-01 | Vertex Pharma | Heteroaryl compounds for pain treatment |
| KR20250120351A (ko) | 2022-12-06 | 2025-08-08 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법 |
| KR20260116140A (ko) | 2023-10-23 | 2026-07-28 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| TW202535867A (zh) | 2023-10-23 | 2025-09-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 |
| KR20260116141A (ko) | 2023-10-23 | 2026-07-28 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료용 화합물 및 이의 고체 형태의 제조방법 |
| KR20260118418A (ko) | 2023-10-23 | 2026-07-30 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| AU2024393245A1 (en) | 2023-12-07 | 2026-06-18 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| TW202606663A (zh) | 2024-06-28 | 2026-02-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| LU605402B1 (en) | 2024-07-11 | 2026-07-14 | Sea4Us Biotecnologia E Recursos Marinhos Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| DE69632684T2 (de) | 1995-06-27 | 2005-06-09 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| EP0946169B1 (en) | 1996-12-20 | 2003-02-26 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| CA2760946C (en) | 2009-05-07 | 2019-06-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for studying, imaging, and treating pain |
| JP6112867B2 (ja) * | 2010-02-10 | 2017-04-12 | ファイトトックス リミテッドＰｈｙｔｏｔｏｘ Ｌｉｍｉｔｅｄ | サキシトキシン誘導体での触覚の喪失の処置 |
| AU2016329201A1 (en) * | 2015-09-30 | 2018-04-26 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
| JP2020515611A (ja) * | 2017-03-29 | 2020-05-28 | サイトワン セラピューティクス， インコーポレイテッド | 疼痛の処置のための１１，１３−修飾サキシトキシン |
| EP3860714B1 (en) * | 2018-10-03 | 2023-09-06 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
-
2021
- 2021-08-14 EP EP21766757.5A patent/EP4196482B1/en active Active
- 2021-08-14 US US18/041,523 patent/US20230339958A1/en active Pending
- 2021-08-14 ES ES21766757T patent/ES3061196T3/es active Active
- 2021-08-14 AU AU2021326546A patent/AU2021326546A1/en active Pending
- 2021-08-14 CA CA3188924A patent/CA3188924A1/en active Pending
- 2021-08-14 JP JP2023511616A patent/JP2023537632A/ja active Pending
- 2021-08-14 WO PCT/US2021/046054 patent/WO2022036297A1/en not_active Ceased
- 2021-08-14 EP EP25205463.0A patent/EP4647075A3/en active Pending
- 2021-08-14 IL IL300626A patent/IL300626A/en unknown
- 2021-08-14 CN CN202180063953.0A patent/CN116368139A/zh active Pending
- 2021-08-14 KR KR1020237008718A patent/KR20230051252A/ko active Pending
- 2021-08-14 MX MX2023001741A patent/MX2023001741A/es unknown
- 2021-08-14 BR BR112023002659A patent/BR112023002659A2/pt unknown
-
2026
- 2026-03-06 JP JP2026036645A patent/JP2026116909A/ja active Pending